Tactile Medical Stock Rises After Positive Flexitouch Trial Results

Zacks Equity Research
4 min read

In This Article:

Tactile Systems Technology, Inc. (TCMD), popularly known as Tactile Medical, has announced positive results from the clinical study evaluating Flexitouch advanced pneumatic compression device (APCD) for treating lower extremity lymphedema in Veterans. The results were published in the Journal of Vascular Surgery, Venous and Lymphatic Disorders.

Data from the study demonstrated substantial improvements in health-related quality of life among veterans after treatment with Flexitouch APCD, the primary endpoint of the study. The use of Flexitouch also led to improvements in patient compliance and limb girth reduction.

Likely Trend of TCMD Stock Following the News

Following the news release, shares of TCMD rose 0.6% to $13.90 at yesterday’s closing.

The recent announcement of positive study results further enhances the company's commitment to improving patient outcomes and quality of life, signaling a promising sentiment around its initiatives. By collaborating with clinicians, Tactile Medical aims to expand clinical evidence and raise awareness, ultimately increasing access to care and reducing healthcare costs for thousands of patients annually.

TCMD's Flexitouch Study Highlights Key Patient Benefits

This 52-week prospective trial, the largest in the United States, examined outcomes in 179 Veterans with lower extremity lymphedema treated with the FlexitouchAPCD. Conducted across four VA medical centers, the study assessed health-related quality of life (QoL) at baseline and at 12, 24 and 52 weeks, along with secondary outcomes like limb circumference, cellulitis events, skin quality and therapy compliance, offering a comprehensive view of the treatment's effectiveness.

In the study, chronic venous insufficiency (phlebolymphedema) emerged as the leading cause of lymphedema, affecting about 63% of participants. Additionally, mild lymphedema was the most prevalent stage of the disease, reported in 68% of patients, highlighting the commonality of these conditions among Veterans undergoing treatment with the Flexitouch device.

Data from the study showed that the use of Flexitouch APCD improved health-related and general quality of life measures, as measured on the Lymphedema QoL scale. The QoL score increased from 6.2 to 6.9 among patients during the study duration. Secondary outcomes showed notable reductions in limb girth (1.4 cm), cellulitis events (from 21.4% to 6.1%) and skin hyperpigmentation (from 75% to 40%). High patient compliance rates of 92% at eight weeks and 72% at 52 weeks further emphasize the therapy's effectiveness.

Recommended Stories